Evidence map›Paper›PMID 36406731›Full record

ArticleHeliyon2022

Structural analysis of a simplified model reproducing SARS-CoV-2 S RBD/ACE2 binding site.

Michela Buonocore, Angelo Santoro, Manuela Grimaldi, Verdiana Covelli, Mohammad Firoznezhad, Manuela Rodriquez, Matteo Santin, Anna Maria D'Ursi

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Michela BuonocoreUniversity of Salerno, Department of Pharmacy, Via Giovanni Paolo II, 132-84084 Fisciano, Salerno, Italy.
Angelo SantoroUniversity of Salerno, Department of Pharmacy, Via Giovanni Paolo II, 132-84084 Fisciano, Salerno, Italy.
Manuela GrimaldiUniversity of Salerno, Department of Pharmacy, Via Giovanni Paolo II, 132-84084 Fisciano, Salerno, Italy.
Verdiana CovelliUniversity of Salerno, Department of Pharmacy, Via Giovanni Paolo II, 132-84084 Fisciano, Salerno, Italy.
Mohammad FiroznezhadUniversity of Salerno, Department of Pharmacy, Via Giovanni Paolo II, 132-84084 Fisciano, Salerno, Italy.
Manuela RodriquezUniversity of Salerno, Department of Pharmacy, Via Giovanni Paolo II, 132-84084 Fisciano, Salerno, Italy.
Matteo SantinCentre for Regenerative Medicine and Devices, School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, BN2 4GJ, UK.
Anna Maria D'UrsiUniversity of Salerno, Department of Pharmacy, Via Giovanni Paolo II, 132-84084 Fisciano, Salerno, Italy.
University of Salerno · ITUniversity of Brighton · GBUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an RNA virus identified as the cause of the coronavirus outbreak in December 2019 (COVID-19). Like all the RNA viruses, SARS-CoV-2 constantly evolves through mutations in its genome, accumulating 1-2 nucleotide changes every month, giving the virus a selective advantage through enhanced transmissibility, greater pathogenicity, and the possibility of circumventing immunity previously acquired by an individual either by natural infection or by vaccination. Several SARS-CoV-2 variants of concern (VoC) have been identified, among which we find Alpha (Lineage B.1.1.7), Beta (Lineage B.1.351), and Gamma (Lineage P.1) variants. Most of the mutations occur in the spike (S) protein, a surface glycoprotein that plays a crucial role in viral infection; the S protein binds the host cell receptor, the angiotensin-converting enzyme of type 2 (ACE2) via the receptor binding domain (RBD) and catalyzes the fusion of the viral membrane with the host cell. In this work, we present the development of a simplified system that would afford to study the change in the SARS-CoV-2 S RBD/ACE2 binding related to the frequent mutations. In particular, we synthesized and studied the structure of short amino acid sequences, mimicking the two proteins' critical portions. Variations in the residues were easily managed through the one-point alteration of the sequences. Nuclear magnetic resonance (NMR) and circular dichroism (CD) spectroscopies provide insights into ACE2 and SARS-CoV-2 S RBD structure with its related three variants (Alpha, Beta, and Gamma). Spectroscopy data supported by molecular dynamics lead to the description of an ACE2/RBD binding model in which the effect of a single amino acid mutation in changing the binding of S protein to the ACE2 receptor is predictable.

Indexed as

ACE2CDCOVID-19MDNMRPeptidesSARS-CoV-2 S RBDStructural biology

Identifiers

PMID36406731
PMCPMC9663143
OpenAlexW4309340363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.